3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Uveal Melanoma
3
Melanoma
2
Leukemia, Myeloid, Acute
2
Carcinoma, Hepatocellular
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Ichthyosis, X-Linked
1
HER2 Negative Metastatic Breast Cancer
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Advanced Solid Cancers
1
Advanced Pancreatic Cancer
1
Interventions
Temozolomide
41
Radiotherapy
15
Magnetic Resonance Spectroscopy
12
Surgical Procedures, Operative
10
Bevacizumab
10
Irinotecan
9
Radiation
8
Nivolumab
7
Carmustine
7
Specimen Handling
6
Radiosurgery
6
Carboplatin
6
ribociclib
5
O(6)-benzylguanine
5
Imiquimod
5
IL13-PE38
5
Flucytosine
5
Filgrastim
5
Erlotinib Hydrochloride
5
Cyclophosphamide
5
Aminolevulinic Acid
5
vandetanib
4
sargramostim
4
Topotecan
4
Lomustine
4
Imatinib Mesylate
4
Etoposide
4
Craniotomy
4
vocimagene amiretrorepvec
3
temsirolimus
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Glioma
×
ADI PEG20
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled